[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Immunis.AI\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":64},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,39],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100366498",false,"NCT04052048","Active Surveillance SNEP Assay Registry Trial for Prostate Cancer","A Multi-center, Prospective Active Surveillance Registry Trial Assessing the Performance of a Non-invasive Immunogenomic Blood Test for Indolent Prostate Cancer Disease Management.","Inclusion Criteria\n\n* Men between 40-80 of age with at least a 10-year life expectancy\n* All active surveillance protocols are accepted\n* No PSA limits\n\nCategory 1:\n\n* Patient is currently on active surveillance with only ONE previous low grade prostate biopsy.\n* Patient must already be scheduled for their 1st annual biopsy under their active surveillance protocol within 90 days of enrollment date.\n\nCategory 2:\n\n• Patient is recently diagnosed with low grade prostate cancer but has decided against active surveillance and is scheduled for radical prostatectomy within 90 days of enrollment date.\n\nExclusion Criteria:\n\nMen on watchful waiting i.e. those with less than 10-year life expectancy with no intent for curative therapy\n\n* Men with symptoms or rising PSA who have not been proven to have cancer by tissue biopsy i.e. men with only negative prostate biopsies.\n* Patients with a history of a different cancer (except basal cell carcinoma)","MALE","40 Years","80 Years",{"count":19,"type":20},2000,"ESTIMATED","10 Years","OBSERVATIONAL","A multi-center, prospective active surveillance registry trial assessing the performance of a non-invasive blood test for indolent prostate cancer disease management.",[25],"Prostate Cancer Aggressiveness","RECRUITING","2026-03-29",{"date":29,"type":30},"2026-04-02","ACTUAL",{"date":32,"type":30},"2019-09-09",{"date":34,"type":20},"2029-09-30",{"name":36,"class":37},"Immunis.AI","INDUSTRY",1,{"id":40,"slug":4,"hasResults":10,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":10,"sex":45,"minAge":46,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":49,"conditions":50,"keywords":53,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":38},"100467709","NCT05370300","SNAPS Breast Cancer Patient Study Breast Cancer Patients","Subtraction Normalized Aggregated Phagocytic Signal in Peripheral Blood of Breast Cancer Patients (SNAPS - Clinical Trial) A NextGen RNASeq Feasibility Study of a Blood-based Model for Early Cancer Detection and Surveillance","Inclusion Criteria:\n\n* Patients \\> 18 yrs of age.\n* Patients diagnosed with stage I-IV breast cancer, who have not begun definitive therapy.\n* Patients undergoing screening mammograms for breast cancer.\n\nExclusion Criteria:\n\n* Patients with a history of a different cancer within the previous 3 years (except non melanoma skin cancer).\n* Any prior treatment (surgery, chemo, hormonal, radiation, biologics, etc.) for current cancer.\n* Any biopsy which resulted in the entire tumor tissue being removed.\n* History of previous breast cancer.\n* Patients unable to provide informed consent.\n* Patients with an abnormal screening mammogram.\n* Patients whose hormone receptor and\u002For HER2 status are not available.","FEMALE","18 Years",{"count":48,"type":20},500,"Differential immunogenomic signatures from peripheral blood CD14 (phagocytic) and CD2 (non-phagocytic) cells have been associated with multiple cancers and disease states. In particular several large clinical studies at Immunis.AI have demonstrated robust immunogenomic signatures in early-stage prostate cancer. Immunis.AI therefore hypothesizes that a peripheral blood immunogenomic signature will identify patients with various stages of breast cancer from healthy negative controls.",[51,52],"Breast Cancer","Breast Cancer Female",[51,54],"Immunogenomics","NOT_YET_RECRUITING","2024-03-05",{"date":58,"type":30},"2024-03-06",{"date":60,"type":20},"2025-09-01",{"date":62,"type":20},"2027-12-31",{"name":36,"class":37},""]